6-я Международная научно-практическая конференция
«Научное издание международного уровня - 2017: мировая практика подготовки и продвижения публикаций»,
(Москва, 18–21 апреля 2017 г.)

Каким образом очень плохие статьи публикуются в очень хороших научных журналах

А.Н. Хохлов, Г.В. Моргунова, А.А. Клебанов

Биологический факультет МГУ имени М.В. Ломоносова, журнал «Вестник Московского университета. Серия 16. Биология»

e-mail: khokhlov@mail.bio.msu.ru


Вестник
Московского
университета
научный
журнал
Серия 16
биология
4/2001


Volume 68, Number 1
January–March 2013
ISSN: 0096-3925
MOSCOW UNIVERSITY
BIOLOGICAL
SCIENCES BULLETIN
English Translation of
Vestnik Moskovskogo Universiteta.
Seriya 16. Biologiya
Editor-in-Chief
Mikhail P. Kirpichnikov
ALLERTON PRESS, INC.
a division of Pleiades Publishing
Distributed by Springer

Количество подписчиков журнала «Moscow University Biological Sciences Bulletin» (электронная + печатная версии) в 2006-2014 гг.



Количество скачанных с сайта *link.springer.com* в 2007-2015 гг. статей из журнала «Moscow University Biological Sciences Bulletin»



Короткая ремарка (не можем удержаться):

О лжепатриотизме в издании научных статей

У кого из присутствующих на ногах – российская обувь? И у кого российский смартфон?

А почему вы непременно хотите печатать статьи на русском?

Просим не рассматривать этот доклад как руководство, хотя…☺

О важности определений

Бабушка покупает рыбу:
- Скажите, а у вас рыба свежая?
- Бабушка, ну как же? Она же живая!
- Ну и что? Я тоже живая…

Хорошие журналы (Top Journals)
Плохие журналы (Top-Less Journals®)

Объективные и субъективные критерии
(как в шоу «Голос»)

Опубликовать «плохую» статью в хорошем журнале – значит, обойти правила, многократно озвученные на этой конференции

Впрочем, в последние дни мы познакомились не только с такими правилами, но и с разными способами обходить требования к регламенту конференции (ПРОГРАММА мероприятия – это его свод согласованных со всеми участниками правил)

О нарушениях грамматических и стилистических ПРАВИЛ многими докладчиками (простите, мое больное место) я уж молчу

А.Ю. Гаспарян упомянул в одном из своих замечательных докладов о странной казахской статье в литовском журнале (WoS)

Главный вопрос, интересующий нас, -

КАК она туда попала?

И каким образом попадают в Nature или Science те достаточно многочисленные статьи, которые потом подвергаются ретракции?

Несколько вариантов (исключительно НАШ взгляд на проблему)

Частные издательства

www.impactjournals.com

IMPACT Journals

New look for the site is coming soon.
We are making it informative, attractive for the authors and readers, easily accessible on different devices.



Please fill out this form to contact our publishing offices. Your email will be routed to the correct department and you will recieve a follow up within 5-7 business days.

Name

Email

Phone

Address

Subject

Message




www.aging-us.com
AGING
SUBMIT AN ARTICLE
Search the Journal
Home
ONLINE ISSN: 1945-4589
NAVIGATE
Home
Editorial Board
Archive
Current Issue
Advance Online Publications
Information For Authors
About the Journal
Contact
Special Collections
Since 2009, Aging (abbreviated by PubMed/Medline as Aging (Albany NY) and by Web of Science as Aging-US) has become a leading journal in the field.
Aging ranks #3 See here
Recent highly cited papers in Aging . See here
Aging a multi-disciplinary journal, publishes on diverse topics in Physiology&Medicine
Papers of Nobel winners in Physiology&Medicine: Elizabeth Blackburn (6 papers), Andrew V. Schally, and Shinya Yamanaka
Aging is approaching its tenth year of publishing. In commemoration of this "Decade in Aging", we are compiling topic-driven special collections. "Special Collection Archives"
Aging is indexed by PubMed/Medline (abbreviated as Aging (Albany NY)), PubMed Central , ISI/Web of Science/Thomson Reuters (abbreviated as Aging-US and listed in the cell biology category), and Scopus /Rank Q1 (abbreviated as Aging).
Latest Issue
Volume 9, Issue 3
Table of Contents
Sign Up for TOC Alerts
INTERVIEWS WITH OUTSTANDING AUTHORS
"Reversal of cognitive decline: A novel therapeutic program"
Dr. Alan Green: Anti-aging treatment today


Oncoscience
Online ISSN: 2331-4737
Search
Home
Editorial Board
Publication Ethics and Publication Malpractice Statements
Information for Authors/Editorial Policies
Submission
Advance Online Publications
Current Issue
Archive
Search
Contact Us
Tweets by @OncoscienceJrnl
Oncoscience @Oncoscien...
Special Promotion - For the promotional price of $20 plus shipping you can
Introducing Oncoscience
Introducing Oncoscience: from Oncotarget to the future
In May 2010, Oncotarget was launched. Just in a couple of years, Oncotarget has received its 2012 impact factor of 6.67, becoming one of the leading journals in oncology and cancer research. The number of submissions is increasing faster than exponentially. Now it is a bi-weekly journal, with dozens of excellent research papers per issue. If this trend continues, Oncotarget may have pretty good odds to attract
1 2 3 4
Oncoscience is an open-access traditional journal with a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
Oncoscience is a peer-reviewed Traditional monthly journal. As a Traditional journal, Oncoscience publishes papers in monthly issues with page numbers. Each issue can be printed for special demand.
Its mission is to cover the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals.
Oncoscience applies the recommendations of the Committee on Publication Ethics (COPE) to all works we publish.
See our papers in PubMed Central(PMC) and PubMed.
Impact Journals, LLC meets the Wellcome Trust Publisher Requirements, and is now a member of the Wellcome Trust List of Compliant Publishers
The Editorial Board includes 20 members of the National Academy of Sciences USA, 6 Lasker Award winners, Nobel Prize winner (Andrew Schally) and other
LATEST ISSUE
Read Online
Submit an Article
View Archive »
Editors-in-Chief
Mikhail V. Blagosklonny
Roswell Park Cancer Institute, Buffalo, NY
Andrei V. Gudkov
Roswell Park Cancer Institute, Buffalo, NY
New Members
Webster Cavenee
University of California, San Diego, CA
Steve J. Elledge
Harvard Medical School, Boston, MA
John T. Isaacs
Johns Hopkins University, Baltimore, MD
Donald W. Kufe
Harvard Medical School, Boston, MA
Charles J. Sherr
St. Jude Children's Research Hospital, Memphis, TN
David Sidransky
Johns Hopkins University, Baltimore, MD
M. Celeste Simon
Univ. Pennsylvania, Philadelphia, PA
Full Editorial Board
Interviews with outstanding authors
Interview with Dr. Apostolos Zaravinos from Molecular Medicine Research Center and Laboratory of Molecular and Medical Genetics Department of Biological Sciences University of


Oncotarget
ONLINE ISSN: 1949-2553
Home
Editorial Board
Publication Ethics and Publication Malpractice Statements
For Authors
Submission
Advance Online Publications
Current Issue
Archive
Contact Information
Search
Sections beyond Oncology
Gerotarget/Aging
Pathology beyond oncology
Immunology and Microbiology
Autophagy and Cell Death
Chromosome
Employment opportunities
Production editor
Read more and apply now
Aging
Genes&Cancer
Spotlight
Maximizing research impact via insightful peer-review
Oncotarget's rising popularity is due to insightful, constructive, punctual, multiple peer-review: helping our authors to increase the impact of their research
Members of Editorial Board Carlo M. Croce (former Editor-in-Chief of Cancer Research) and Andrew Schally (Nobel Prize winner)have published 27 and 10 papers in Oncotarget
Since 2013, 4 members of Oncotarget/Oncoscience/Gerotarget won Breakthrough Prize, the highest prize ever: Bert Vogelstein, Michael N. Hall, Alexander Varshavsky, Stephen J. Elledge
Oncotarget sponsors Gordon Research Conference.
Interviews with outstanding authors
See more on Oncotarget in global News
Oncotarget is accepting papers on topics beyond oncology: Neuroscience, Endocrinology, Cardiology, Metabolism, Cell Biology, Pharmacology (all areas) and more
Impact factor (IF) Thomson Reuters JCR
Year IF Total Cites
2015/2016 5.008 10452
2014 6.359 3908
2013 6.627 2217
2012 6.636 1450
2011 4.784 493
FORECAST: Our preliminary analysis of the Web of Science Core Collection (1/23/17), shows that there is a potential rise in the Thomson Reuters 2016 Impact Factor for Oncotarget coming in summer of 2017
2015/2016: 5-Year Impact Factor: 5.415
Scopus/SJR ranking: 2011-ongoing: Q1 (highest rank). All years Q1 in Medicine (subject area) and Oncology
Current Issue
Oncotarget
18 April 2017 | V8N16
Indexed in MEDLINE/PubMed, Pubmed Central, ISI/Web of Science: Science Citation Index Expanded, Scopus, Biological Abstracts, BIOSIS Previews, EMBASE
Impact Journals, LLC meets the Wellcome Trust Publisher Requirements, and is now a member of the Wellcome Trust List of Compliant Publishers
Interviews with outstanding authors
Editors-in-Chief
Andrei V. Gudkov
Roswell Park Cancer Institute, Buffalo, NY
Mikhail V. Blagosklonny
Roswell Park Cancer Institute, Buffalo, NY
Editorial Board
Frederick Alt
Harvard Medical School, Boston, MA
Carlo M. Croce
The Ohio State University, Columbus, OH
Ronald A. DePinho
The University of Texas MD Anderson Cancer Center
Brian J. Druker
Oregon Health Science Univ, Portland, OR


www.tandfonline.com/loi/kccy20
Taylor & Francis Online
Log in | Register
Cart
Journal
Cell Cycle
Back to journal
Enter keywords, authors, DOI etc.
This journal
This journal
Aims and scope
Instructions for authors
Journal information
Editorial board
Related websites
Advertising information
Subscribe
Sample Our Bioscience journals
Publication history
List of issues
Latest articles
Volume 16 2017
Volume 15 2016
Volume 14 2015



Editorial activities [edit]

Blagosklonny is editor-in-chief of *Aging*,[4] *Cell Cycle*,[5] and *Oncotarget*.[6] In addition, he is associate editor of *Cancer Biology & Therapy*[7] and a member of the editorial board of *Cell Death & Differentiation*.[8]

The reviewing process employed by *Oncotarget* has been criticized by Jeffrey Beall,[9] who also included *Oncotarget* and *Aging* on his list of "potential, possible, or probable predatory scholarly open-access journals"[10] in July 2015.[9] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editor-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal impact factor.[11]

www.scimagojr.com/journalsearch.php

Oncotarget

Country	United States
Subject Area and Category	Medicine Oncology
Publisher	Impact Journals
Publication type	Journals
ISSN	19492553
Coverage	2010-ongoing

46
H Index













need to explore therapeutic strategies that target the identified pathways, not only in the striatum but also in other brain areas besides the basal ganglia which has been underestimated and are strongly involved in HD cognitive pathology

Silvia Ginés: Departament de Biologia Cel·lular, Immunologia i Neurociències, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain; Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; CIBERNED, Spain

Correspondence to: *Silvia Ginés,* ***email*** *silviagines@ub.edu*

Keywords: Huntington´s disease, cognitive deficits, hippocampus, p75 receptor, RhoA

Received: *December 03, 2015*

Published: *December 17, 2015*

REFERENCES

1. Zuccato C. and Cattaneo E, et al. Prog Neurobiol. 2007; 81:294-330.
2. Brito V, et al. Cell Death Dis. 2013; 4:e595.
3. Plotkin JL, et al. Neuron. 2014; 83:178-88.
4. Brito, et al. J Clin Invest. 2014; 124:4411-28.
5. Nakayama AY, et al. J Neurosci. 2000; 20:5329-5338.
6. Miguez A, et al. Hum Mol Genet. 2015; 24:4958-70.


www.aging-us.com
AGING
SUBMIT AN ARTICLE
Search the Journal
Home
ONLINE ISSN: 1945-4589
NAVIGATE
Home
Editorial Board
Archive
Current Issue
Advance Online Publications
Information For Authors
About the Journal
Contact
Special Collections
Since 2009, Aging (abbreviated by PubMed/Medline as Aging (Albany NY) and by Web of Science as Aging-US) has become a leading journal in the field.
Aging ranks #3 See here
Recent highly cited papers in Aging . See here
Aging a multi-disciplinary journal, publishes on diverse topics in Physiology&Medicine
Papers of Nobel winners in Physiology&Medicine: Elizabeth Blackburn (6 papers), Andrew V. Schally, and Shinya Yamanaka
Aging is approaching its tenth year of publishing. In commemoration of this "Decade in Aging", we are compiling topic-driven special collections. "Special Collection Archives"
Aging is indexed by PubMed/Medline (abbreviated as Aging (Albany NY)), PubMed Central , ISI/Web of Science/Thomson Reuters (abbreviated as Aging-US and listed in the cell biology category), and Scopus /Rank Q1 (abbreviated as Aging).
Latest Issue
Volume 9, Issue 3
Table of Contents
Sign Up for TOC Alerts
INTERVIEWS WITH OUTSTANDING AUTHORS
"Reversal of cognitive decline: A novel therapeutic program"
Dr. Alan Green: Anti-aging treatment today


Oncoscience
Online ISSN: 2331-4737
Search
Home
Editorial Board
Publication Ethics and Publication Malpractice Statements
Information for Authors/Editorial Policies
Submission
Advance Online Publications
Current Issue
Archive
Search
Contact Us
Tweets by @OncoscienceJrnl
Introducing Oncoscience
Introducing Oncoscience: from Oncotarget to the future
Oncoscience is an open-access traditional journal with a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
Oncoscience is a peer-reviewed Traditional monthly journal. As a Traditional journal, Oncoscience publishes papers in monthly issues with page numbers. Each issue can be printed for special demand.
Its mission is to cover the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals.
Oncoscience applies the recommendations of the Committee on Publication Ethics (COPE) to all works we publish.
See our papers in PubMed Central(PMC) and PubMed.
Impact Journals, LLC meets the Wellcome Trust Publisher Requirements, and is now a member of the Wellcome Trust List of Compliant Publishers
The Editorial Board includes 20 members of the National Academy of Sciences USA, 6 Lasker Award winners, Nobel Prize winner (Andrew Schally) and other
LATEST ISSUE
Read Online
Submit an Article
View Archive
Editors-in-Chief
Mikhail V. Blagosklonny
Roswell Park Cancer Institute, Buffalo, NY
Andrei V. Gudkov
Roswell Park Cancer Institute, Buffalo, NY
New Members
Webster Cavenee
University of California, San Diego, CA
Steve J. Elledge
Harvard Medical School, Boston, MA
John T. Isaacs
Johns Hopkins University, Baltimore, MD
Donald W. Kufe
Harvard Medical School, Boston, MA
Charles J. Sherr
St. Jude Children's Research Hospital, Memphis, TN
David Sidransky
Johns Hopkins University, Baltimore, MD
M. Celeste Simon
Univ. Pennsylvania, Philadelphia, PA
Full Editorial Board
Interviews with outstanding authors


Oncotarget
ONLINE ISSN: 1949-2553
Home
Editorial Board
Publication Ethics and Publication Malpractice Statements
For Authors
Submission
Advance Online Publications
Current Issue
Archive
Contact Information
Search
Sections beyond Oncology
Gerotarget/Aging
Pathology beyond oncology
Immunology and Microbiology
Autophagy and Cell Death
Chromosome
Employment opportunities
Production editor
Read more and apply now
Aging
Genes&Cancer
Spotlight
Maximizing research impact via insightful peer-review
Oncotarget's rising popularity is due to insightful, constructive, punctual, multiple peer-review: helping our authors to increase the impact of their research
Members of Editorial Board Carlo M. Croce (former Editor-in-Chief of Cancer Research) and Andrew Schally (Nobel Prize winner)have published 27 and 10 papers in Oncotarget
Since 2013, 4 members of Oncotarget/Oncoscience/Gerotarget won Breakthrough Prize, the highest prize ever: Bert Vogelstein, Michael N. Hall, Alexander Varshavsky, Stephen J. Elledge
Oncotarget sponsors Gordon Research Conference.
Interviews with outstanding authors
See more on Oncotarget in global News
Oncotarget is accepting papers on topics beyond oncology: Neuroscience, Endocrinology, Cardiology, Metabolism, Cell Biology, Pharmacology (all areas) and more
Impact factor (IF) Thomson Reuters JCR
Year IF Total Cites
2015/2016 5.008 10452
2014 6.359 3908
2013 6.627 2217
2012 6.636 1450
2011 4.784 493
FORECAST: Our preliminary analysis of the Web of Science Core Collection (1/23/17), shows that there is a potential rise in the Thomson Reuters 2016 Impact Factor for Oncotarget coming in summer of 2017
2015/2016: 5-Year Impact Factor: 5.415
Scopus/SJR ranking: 2011-ongoing: Q1 (highest rank). All years Q1 in Medicine (subject area) and Oncology
Current Issue
Oncotarget
18 April 2017 | V8N16
Indexed in MEDLINE/PubMed, Pubmed Central, ISI/Web of Science: Science Citation Index Expanded, Scopus, Biological Abstracts, BIOSIS Previews, EMBASE
Impact Journals, LLC meets the Wellcome Trust Publisher Requirements, and is now a member of the Wellcome Trust List of Compliant Publishers
Interviews with outstanding authors
Editors-in-Chief
Andrei V. Gudkov
Roswell Park Cancer Institute, Buffalo, NY
Mikhail V. Blagosklonny
Roswell Park Cancer Institute, Buffalo, NY
Editorial Board
Frederick Alt
Harvard Medical School, Boston, MA
Carlo M. Croce
The Ohio State University, Columbus, OH
Ronald A. DePinho
The University of Texas MD Anderson Cancer Center
Brian J. Druker
Oregon Health Science Univ, Portland, OR


www.tandfonline.com/loi/kccy20
Taylor & Francis Online
Log in | Register | Cart
Journal
Cell Cycle
Back to journal
Enter keywords, authors, DOI etc.
This journal
This journal
Aims and scope
Instructions for authors
Journal information
Editorial board
Related websites
Advertising information
Subscribe
Sample Our Bioscience journals
Publication history
List of issues
Latest articles
Volume 16 2017
Volume 15 2016
Volume 14 2015

ГЕРОНТОЛОГИЯ

УДК 576.35:57.017.6

pH КУЛЬТУРАЛЬНОЙ СРЕДЫ И "СТАЦИОНАРНОЕ"/ХРОНОЛОГИЧЕСКОЕ СТАРЕНИЕ РАЗЛИЧНЫХ КЛЕТОК

Г.В. Моргунова[1], А.А. Клебанов[1], Ф. Маротта[2], А.Н. Хохлов[1,*]

[1] *Сектор эволюционной цитогеронтологии, биологический факультет, Московский государственный университет имени М.В. Ломоносова, Россия, 119234, Москва, Ленинские горы, д. 1, стр. 12;*
[2] *ReGenera Research Group for Aging Intervention and San Babila Clinic, Corso Matteotti 1/A, 20121 Milano, Italy*
**e-mail: khokhlov@mail.bio.msu.ru*

Существует точка зрения, согласно которой хронологическое старение (ХС) дрожжей и "стационарное" старение (СС) культивируемых клеток человека и животных являются следствием закисления ростовой среды. Однако целый ряд появившихся в последнее время работ свидетельствует о том, что этот процесс хотя и влияет в определенной степени на скорость "старения" клеток в стационарной фазе, но не определяет его полностью. По-видимому, определяющим фактором здесь является ограничение клеточной пролиферации, которое приводит к "старению" клеток даже в физиологически оптимальных условиях. При ХС дрожжей и при СС клеток млекопитающих ростовая среда закисляется до pH≤4. Если не допускать накопления кислоты в среде, можно увеличить продолжительность жизни культуры, однако клетки всё равно будут вымирать, только с меньшей скоростью. Наблюдаемые эффекты закисления среды при ХС и СС могут объясняться активацией высоко консервативных сигнальных путей роста, приводящих к развитию окислительного стресса, а эти процессы, в свою очередь, могут быть вовлечены в старение многоклеточных организмов и связаны с возникновением у них возрастных заболеваний. Ранее мы изучали влияние буферной ёмкости культуральной среды на СС трансформированных клеток китайского хомячка. Было установлено, что наличие в среде HEPES в концентрации 20 мМ не влияет на скорость роста клеток. При этом ростовые кривые выходили на "плато" в один и тот же день. Однако в среде с HEPES клетки, с одной стороны, достигали меньшей насыщающей плотности, чем в контроле (т.е. были "старше" согласно критериям геронтологической клеточно-кинетической модели), а с другой – претерпевали СС с гораздо меньшей скоростью (но все равно "старели"). Можно полагать, что внеклеточный pH, который, кстати, хорошо коррелирует с внутриклеточным, является хотя и важным (концепция И.А. Аршавского о роли ацидотической альтерации в старении), но не ключевым фактором, определяющим выживание клеток в стационарной культуре.

Ключевые слова: *pH ростовой среды, буферная емкость, клеточные культуры, "стационарное старение", хронологическое старение, обзор*

www.impactaging.com AGING, November 2011, Vol 3 N 11

Research Paper

Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression

Olga V. Leontieva and Mikhail V. Blagosklonny

Department of Cell Stress Biology, Roswell Park Cancer Institute, BLSC, L3-312, Buffalo, NY, 14263, USA

Key words: *chronological aging, senescence, metabolism, rapamycin, mTOR, lactate*
Received: *09/15/11; Accepted: 12/9/11; Published: 12/10/11*
Correspondence to: *Mikhail V. Blagosklonny, MD/PhD;* ***E-mail:*** *blagosklonny@oncotarget.com*

Abstract: **In yeast, chronological senescence (CS) is defined as loss of viability in stationary culture. Although its relevance to the organismal aging remained unclear, yeast CS was one of the most fruitful models in aging research. Here we described a mammalian replica of yeast CS: loss of viability of overgrown "yellow" cancer cell culture. In a density and time (chronological)-dependent manner, cell culture loses the ability to re-grow in fresh medium. Rapamycin dramatically decelerated CS. Loss of viability was caused by acidification of the medium by lactic acid (lactate). Rapamycin decreased production of lactate, making conditioned medium (CM) less deadly. Both deadly CM and lactate caused loss of viability in low cell density, not preventable by either rapamycin or additional glucose. Also, NAC, LY294002, U0126, GSK733, which all**

www.impactaging.com AGING, November 2011, Vol 3 N 11

Editorial Comment

Chronological lifespan in stationary culture: from yeast to human cells

Zoya N. Demidenko

Comment on: Leontieva OV and Blagosklonny MV. Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. Aging 2011; 3: this issue

A decade ago, Mikhail Blagosklonny predicted that cellular senescence is driven by mitogenic pathways, when the cell cycle is blocked and actual growth is impossible [1]. In particular, the mitogen- and nutrient-sensing mTOR (Target of Rapamycin) pathway drives either cell mass growth or aging [2]. Rapamycin prevents conversion of reversible cell cycle arrest to senescence [3-11]. When the cell cycle is blocked, but mTOR is still active, then cells become senescent. This process was named *gerogenic conversion* or simply *geroconversion* [12]. Rapamycin did not by-pass arrest but suppress geroconversion. Cells remained resting but not senescent. The discovery of mTOR-dependent geroconversion allowed Blagosklonny to connect cellular aging to age-related diseases and organismal aging [13, 14]. Furthermore, this predicted that rapamycin is a gerosuppressant, which could be used to prevent age-related diseases by slowing down the aging

lytic cells can destroy cell culture. But like it was known to most researches (90 years ago) that fungi can destroy bacterial culture, it took a special insight to recognize the potential of this seemingly useless phenomenon. There is an intriguing parallel between penicillin and rapamycin. As described in this issue of *Aging*, mTOR pathway is involved in glycolytic phenotype, causing self-poisoning due to over-production of lactic acid. By decreasing lactate production, rapamycin prevents chronological senescence (CS). CS can be manipulated genetically and pharmacologically. Most importantly, the same agents that suppress geroconversion, organismal aging and cancer also suppress CS.

This study does not break any dogma because there was no dogma as the field did not exist. This paper opens a new filed in both aging and cancer research.

ActaNaturae

ISSN: 2075-8251 (English edition), 2075-8243 (Russian edition)

Acta Naturae. 2017.
V. 9. № 1 (32)



About

New journal on life sciences, biotechnology and biopharmaceutics

Journal "Acta Naturae" is now available in open access in PubMed Central® and eLIBRARY.RU.

Acta Naturae is a new international journal on life sciences based in Moscow, Russia. Our goal is to present scientific work and discovery in molecular biology, biochemistry, biomedical disciplines and biotechnology. These fields represent the most important priorities for the research and engineering development both in Russia and worldwide. Acta Naturae is also a periodical for those who are curious in various aspects of biotechnological business, innovations in pharmaceutical areas, intellectual property protection and social consequences of scientific progress. The journal will publish analytical industrial surveys focused

To send the article

Правила для авторов

Acta Naturae

Country	Russian Federation
Subject Area and Category	Biochemistry, Genetics and Molecular Biology Biochemistry Biotechnology Molecular Biology Molecular Medicine
Publisher	Park Media Ltd.
Publication type	Journals
ISSN	20758251
Coverage	2013-ongoing

8
H Index

Quartiles



SJR



Citations per document



Total Cites · Self-Cites

External Cites per Doc · Cites per Doc



% International Collaboration



Citable documents · Non-citable documents



Cited documents · Uncited documents



← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href='http://www.scimag
```

Частные издательства в обоих случаях. Они не связаны с необходимостью соблюдать все правила больших международных издательств

При этом не очень важно, берут ли они за публикации деньги (Aging et al.) или нет (AN)

Кроме того:

- Спецвыпуски (приглашенные редакторы)
- Наличие «паровоза» (про журнал с ИФ 29)
- Активность/скважистость
- После достижения определенной планки – будет гораздо легче (может, даже – как по маслу)
- Поиск «хороших» журналов с «портфельными» проблемами (например, сезонными)
- Указание имен подходящих и неподходящих рецензентов

Впрочем, есть еще один вариант – улучшить «плохую» статью, приведя ее в соответствие с требованиями «хороших» журналов (стиль, данные, правильный английский язык, корректно оформленный список литературы и т.п.). Но об этом подходе на нашей конференции уже говорили сотни раз…

Уметь говорить для оратора менее важное достоинство, нежели уметь остановиться

Сенека

Когда человек говорит мало, он кажется умнее

Максим Горький

Спасибо за внимание/терпение!